News

New Finasteride genetic test avaliable

HairDX, LLC, a subsidiary of PharmaGenoma, Inc., is bringing out a genetic diagnostic to anticipate clinical reply to finasteride, a frequently prescribed hair loss medication (a.k.a. as Propecia, among various names). Finasteride functions by blocking the creation of the androgens responsible for hair loss in androgenic alopecia.

Employment of these medicament bears a chance of sexual side effects and since hair grows in cycles, it frequently takes months to find out if it’s functioning. The genetic test, brought out at the yearly meeting of The American Academy of Dermatology, allows patients with a grade that forecasts their reaction to finasteride. The test acts by keying out certain nucleoside variates along the androgen receptor gene that regulate androgen predisposition.

From the press release:

The HairDX (RxR) Genetic Test for Finasteride reaction will aid doctors predetermine whenever patients will have a subtle, average, or good treatment reply to Finasteride, granting the physician to supply patients with the most effective treatment regime to preserve their hair…

The test offers doctors with a patient grade, named the CAG repeat score. “A smaller CAG test score is associated with an increased response to Finasteride for treatment of Androgenetic Alopecia,” says Dr. Sharon Keene, HairDX Chief Medical Officer. “Scientists discovered that among men that had the best response to Finasteride approximately 70% had a CAG score beneath 22 while among men that had a subtle response to Finasteride approximately 70% had a CAG score above 22.”

Product page: HairDX

© 2009 Hairlossline – hair loss.